| 1.23 -0.12 (-8.89%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.73 |
1-year : | 1.94 |
| Resists | First : | 1.48 |
Second : | 1.66 |
| Pivot price | 1.31 |
|||
| Supports | First : | 1.19 | Second : | 0.99 |
| MAs | MA(5) : | 1.29 |
MA(20) : | 1.34 |
| MA(100) : | 3.13 |
MA(250) : | 12.16 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 40.7 |
| RSI | RSI(14): 29 |
|||
| 52-week | High : | 44.77 | Low : | 1.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 15.3%. Bollinger Bands are 81% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.35 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Tue, 03 Mar 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Sheboygan Press
Thu, 26 Feb 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - Weatherford Democrat
Thu, 26 Feb 2026
Kidney drug Gemini advances at Revelation, cash runway into 2027 - Stock Titan
Mon, 26 Jan 2026
Revelation Biosciences to implement 1-for-4 reverse stock split - Investing.com
Mon, 26 Jan 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Newswire.com
Fri, 23 Jan 2026
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 8.2 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | 325 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -62.3 % |
| Return on Equity (ttm) | -131.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|